Pfizer Inc. (NYSE:PFE) Shares Purchased by Pzena Investment Management LLC

Pzena Investment Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,058,981 shares of the biopharmaceutical company's stock after acquiring an additional 107,402 shares during the quarter. Pzena Investment Management LLC owned approximately 0.12% of Pfizer worth $178,875,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of PFE. Providence Capital Advisors LLC grew its position in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after buying an additional 409 shares during the period. William B. Walkup & Associates Inc. grew its position in shares of Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co grew its position in shares of Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 467 shares during the period. Sutton Place Investors LLC grew its position in shares of Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the period. Finally, Bellevue Group AG grew its position in shares of Pfizer by 0.3% in the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after purchasing an additional 485 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Down 0.1%

Shares of PFE traded down $0.02 during trading on Thursday, reaching $24.59. 47,333,190 shares of the company traded hands, compared to its average volume of 41,955,789. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market cap of $139.83 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. The stock has a 50-day simple moving average of $23.99 and a 200-day simple moving average of $24.77. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the business earned $0.82 earnings per share. The business's revenue for the quarter was down 7.8% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.99%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Citigroup lifted their target price on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Jefferies Financial Group lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley lifted their target price on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. TD Cowen decreased their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. Finally, Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.